XML 75 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Goodwill And Intangible Assets
3 Months Ended
Mar. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill And Intangible Assets
Goodwill and Intangible Assets
The changes in the carrying amount of goodwill for the three months ended March 31, 2013 are as follows:
(In thousands)
Generics
Segment
 
Specialty
Segment
 
Total
Balance at December 31, 2012:
 
 
 
 
 
Goodwill
$
3,194,148

 
$
706,507

 
$
3,900,655

Accumulated impairment losses

 
(385,000
)
 
(385,000
)
 
3,194,148

 
321,507

 
3,515,655

Goodwill acquired (1)
10,213

 

 
10,213

Transfers (2)
(27,602
)
 
27,602

 

Foreign currency translation
(74,362
)
 

 
(74,362
)
 
$
3,102,397

 
$
349,109

 
$
3,451,506

Balance at March 31, 2013:
 
 
 
 
 
Goodwill
$
3,102,397

 
$
734,109

 
$
3,836,506

Accumulated impairment losses

 
(385,000
)
 
(385,000
)
 
$
3,102,397

 
$
349,109

 
$
3,451,506


____________
(1) 
See Note 4.
(2) 
As a result of the January 1, 2013 reorganization of certain components between the Generics and Specialty segments, the Company was required to reassign a portion of the carrying amount of goodwill to the Specialty segment.
Intangible assets consist of the following components at March 31, 2013 and December 31, 2012:
(In thousands)
Weighted
Average Life
(Years)
 
Original
Cost
 
Accumulated
Amortization
 
Net Book
Value
March 31, 2013
 
 
 
 
 
 
 
Amortized intangible assets:
 
 
 
 
 
 
 
Patents and technologies
20
 
$
116,631

 
$
89,656

 
$
26,975

Product rights and licenses
10
 
3,411,312

 
1,794,267

 
1,617,045

Other (1)
8
 
106,701

 
58,309

 
48,392

 
 
 
3,634,644

 
1,942,232

 
1,692,412

In-process research and development
 
 
413,028

 

 
413,028

 
 
 
$
4,047,672

 
$
1,942,232

 
$
2,105,440

December 31, 2012
 
 
 
 
 
 
 
Amortized intangible assets:
 
 
 
 
 
 
 
Patents and technologies
20
 
$
116,631

 
$
88,288

 
$
28,343

Product rights and licenses
10
 
3,459,980

 
1,749,424

 
1,710,556

Other (1)
8
 
111,033

 
51,384

 
59,649

 
 
 
3,687,644

 
1,889,096

 
1,798,548

In-process research and development
 
 
425,909

 

 
425,909

 
 
 
$
4,113,553

 
$
1,889,096

 
$
2,224,457

____________
(1) 
Other intangible assets consist principally of customer lists and contracts.
Amortization expense, which is classified primarily within cost of sales in the Condensed Consolidated Statements of Operations, for the three months ended March 31, 2013 and 2012, was $91.5 million and $87.8 million, respectively. Amortization expense is expected to be approximately $260 million for the remainder of 2013 and $339 million, $317 million, $244 million and $199 million for the years ended December 31, 2014 through 2017, respectively.
Indefinite-lived intangible assets, such as the Company’s in-process research and development (“IPR&D”) assets, are tested at least annually for impairment, but may be tested whenever certain impairment indicators are present. Impairment is determined to exist when the fair value is less than the carrying value of the assets being tested. During the three months ended March 31, 2013, the Company recognized IPR&D impairment charges of $5.1 million, which were recorded as a component of amortization expense.
During the three months ended March 31, 2013 and 2012, approximately $6.5 million and $33.0 million, respectively, were reclassified from acquired IPR&D to product rights and licenses.